Search > Results
You searched for: EV210101 (EV-TRACK ID)
Showing 1 - 6 of 6
Showing 1 - 6 of 6
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV210101 | 4/6 | Homo sapiens | Urine |
(d)(U)C Filtration SEC (non-commercial) |
Welton, Joanne Louise | 2016 | 67% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
67% (94th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Urine
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Filtration Size-exclusion chromatography (non-commercial) Protein markers
EV: Alix/ TSG101/ LAMP2A
non-EV: Albumin Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Urine
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
Type 70 Ti
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
2.8
Sample volume/column (mL)
0.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
Western Blot
Detected EV-associated proteins
Alix/ LAMP2A/ TSG101
Not detected contaminants
Albumin
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
117.75
EV concentration
Yes
Particle yield
As the number of particles per µg protein;Yes, other: 20000000000
EM
EM-type
Cryo-EM
Image type
Close-up
|
||||||||
EV210101 | 3/6 | Homo sapiens | Blood plasma |
(d)(U)C SEC (non-commercial) Filtration |
Welton, Joanne Louise | 2016 | 50% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
50% (82nd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Size-exclusion chromatography (non-commercial) Filtration Protein markers
EV: CD81/ CD9
non-EV: Albumin/ ApoB Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
TLA-110
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
12
Sample volume/column (mL)
1.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
ELISA
Detected EV-associated proteins
CD81/ CD9
Detected contaminants
ApoB
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
86.47
EV concentration
Yes
Particle yield
As the number of particles per µg protein;Yes, other: 5000000000
EM
EM-type
Cryo-EM
Image type
Close-up
|
||||||||
EV210101 | 1/6 | Homo sapiens | Blood plasma |
(d)(U)C SEC (non-commercial) Filtration |
Welton, Joanne Louise | 2016 | 29% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
29% (59th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Metastatic prostate cancer, failed treatment
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Size-exclusion chromatography (non-commercial) Filtration Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
TLA-110
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
12
Sample volume/column (mL)
1.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210101 | 2/6 | Homo sapiens | Blood plasma |
(d)(U)C SEC (non-commercial) Filtration |
Welton, Joanne Louise | 2016 | 29% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
29% (59th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Mestatatic prostate cancer, prior treatment
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Size-exclusion chromatography (non-commercial) Filtration Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
TLA-110
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
12
Sample volume/column (mL)
1.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210101 | 5/6 | Homo sapiens | Urine |
(d)(U)C Filtration SEC (non-commercial) |
Welton, Joanne Louise | 2016 | 29% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
29% (60th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Urine
Sample origin
Metastatic prostate cancer, failed treatment
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Filtration Size-exclusion chromatography (non-commercial) Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Urine
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
Type 70 Ti
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
2.8
Sample volume/column (mL)
0.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
EV210101 | 6/6 | Homo sapiens | Urine |
(d)(U)C Filtration SEC (non-commercial) |
Welton, Joanne Louise | 2016 | 29% | |
Study summaryFull title
All authors
Joanne Louise Welton, Paul Brennan, Mark Gurney, Jason Paul Webber, Lisa Kate Spary, David Gil Carton, Juan Manuel Falcón-Pérez, Sean Peter Walton, Malcolm David Mason, Zsuzsanna Tabi, Aled Clayton
Journal
J Extracell Vesicles
Abstract
Proteomics analysis of biofluid-derived vesicles holds enormous potential for discovering non-invasi (show more...)
EV-METRIC
29% (60th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Urine
Sample origin
Mestatatic prostate cancer, prior treatment
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
Filtration Size-exclusion chromatography (non-commercial) Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Identification of content (omics approaches)/Technical analysis comparing/optimizing EV-related methods
Sample
Species
Homo sapiens
Sample Type
Urine
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Equal to or above 150,000 g Pelleting performed
Yes
Pelleting: time(min)
120
Pelleting: rotor type
Type 70 Ti
Pelleting: speed (g)
200000
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
2.8
Sample volume/column (mL)
0.5
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Other;Spectrophotometry
Detected EV-associated proteins
SOMAscan multiplex assay
Characterization: Lipid analysis
No
Characterization: Particle analysis
None
|
||||||||
1 - 6 of 6 |
EV-TRACK ID | EV210101 | |||||
---|---|---|---|---|---|---|
species | Homo sapiens | |||||
sample type | Urine | Blood plasma | Blood plasma | Blood plasma | Urine | Urine |
condition | Control condition | Control condition | Metastatic prostate cancer failed treatment | Mestatatic prostate cancer prior treatment | Metastatic prostate cancer failed treatment | Mestatatic prostate cancer prior treatment |
separation protocol | (d)(U)C Filtration Size-exclusion chromatography (non-commercial) | (d)(U)C Size-exclusion chromatography (non-commercial) Filtration | (d)(U)C Size-exclusion chromatography (non-commercial) Filtration | (d)(U)C Size-exclusion chromatography (non-commercial) Filtration | (d)(U)C Filtration Size-exclusion chromatography (non-commercial) | (d)(U)C Filtration Size-exclusion chromatography (non-commercial) |
Exp. nr. | 4 | 3 | 1 | 2 | 5 | 6 |
EV-METRIC % | 67 | 50 | 29 | 29 | 29 | 29 |